Okabena Investment Services Inc. Decreases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Okabena Investment Services Inc. trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 38.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,450 shares of the company's stock after selling 22,326 shares during the quarter. Okabena Investment Services Inc.'s holdings in Teva Pharmaceutical Industries were worth $803,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after buying an additional 496 shares during the last quarter. Sanctuary Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after acquiring an additional 664 shares during the period. Thrivent Financial for Lutherans raised its stake in Teva Pharmaceutical Industries by 0.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after acquiring an additional 699 shares during the last quarter. Metis Global Partners LLC lifted its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after acquiring an additional 860 shares during the period. Finally, DGS Capital Management LLC grew its stake in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after purchasing an additional 872 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Thursday, March 27th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Finally, Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded down $0.03 during mid-day trading on Wednesday, reaching $15.26. 4,286,571 shares of the stock were exchanged, compared to its average volume of 12,201,059. The company has a market capitalization of $17.30 billion, a P/E ratio of -10.52, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business's 50 day moving average is $16.95 and its 200-day moving average is $18.08. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.